drugset / Trial / NCT00938405

Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus

NCT00938405

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a prospective, randomized, double blind, parallel, placebo controlled clinical trial evaluating the efficacy of colesevelam HCl in reducing LDL in subjects with type 1 diabetes mellitus over a 12 week treatment period. The aim is to highlight the effect of colesevelam on LDL cholesterol and glycemia in a type 1 diabetic population. The colesevelam group is anticipated to demonstrate a mean reduction in LDL by 10% compared to the placebo group, indicated by A1c and glycemic target range CGM readings.

Timeline

Start
2009-07
Primary completion
2009-12
Completion
2009-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Colesevelam Other / unclassified 3.75 g Oral